Combined biodifferentiating and antiangiogenic oral metronomic
therapy is feasible and effective in relapsed solid tumors in
children: single-center pilot study.

J 2006

Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study.

ŠTĚRBA, Jaroslav; Dalibor VALÍK; Peter MÚDRY; Tomáš KEPÁK; Zdeněk PAVELKA et al.

Základní údaje

Originální název

Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study.

Název česky

Protokol COMBAT v léčbě relabovaných dětských nádorů: zkušenost jednoho centra.

Autoři

ŠTĚRBA, Jaroslav; Dalibor VALÍK; Peter MÚDRY; Tomáš KEPÁK; Zdeněk PAVELKA; Viera BAJČIOVÁ; Karel ZITTERBART; Věra KADLECOÁ a Pavel MAZÁNEK

Vydání

Onkologie, Switzerland, Karger, 2006, 0378-584X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.724

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/06:00036137

Organizační jednotka

Lékařská fakulta

UT WoS

000238947800002

Klíčová slova česky

dětské nádory; metronomická léčba; bioterapie

Klíčová slova anglicky

childhood cancer; metronomic therapy; biotherapy

Štítky

biotherapy, childhood cancer, metronomic therapy

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 4. 2010 23:59, MUDr. Karel Zitterbart, Ph.D.

Anotace

ORIG CZ

V originále

Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study.To outline an outpatient-based treatment for children with relapsed solid tumors, who already have been extensively pretreated, we defined a 4-drug protocol named COMBAT (combined oral maintenance biodifferentiating and antiangiogenic therapy). Using this protocol, we performed a pilot study to determine its feasibility in children with relapsed and/or high-risk pediatric solid tumors. Patients and Methods: 22 children received the COMBAT protocol. Treatment consisted of daily celecoxib administration along with daily 13-cisretinoic acid (2 weeks on / 2 weeks off) and cycles of metronomic temozolomide (90 mg/m2 for 42 days) and low-dose etoposide (21 days). The treatment was scheduled for a period of 1 year. Results: 9 of the 14 patients assessable for response demonstrated evidence of treatment benefit manifested as prolonged disease stabilization or response. The protocol medication was well tolerated with very good compliance. Only minimal side effects where observed which responded to dose modification or local therapy. Conclusions: The COMBAT regimen is well tolerated by patients with intensive prior therapy including myeloablative regimens. Favorable responses observed in this cohort of patients support the further exploration of this and/or similar strategies in the treatment of pediatric solid tumors.

Česky

Protokol COMBAT v léčbě relabovaných dětských nádorů: zkušenost jednoho centra.

Návaznosti

NR8448, projekt VaV

Název: Charakterizace genové exprese leukemických buněk pomocí DNA čipů a její využití pro molekulární diagnostiku a predikci odpovědi na léčbu

Citovat

ŠTĚRBA, Jaroslav; Dalibor VALÍK; Peter MÚDRY; Tomáš KEPÁK; Zdeněk PAVELKA; Viera BAJČIOVÁ; Karel ZITTERBART; Věra KADLECOÁ a Pavel MAZÁNEK. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie. Switzerland: Karger, 2006, roč. 29, č. 7, s. 308-313, 5 s. ISSN 0378-584X.

@article{839465,
   author = {Štěrba, Jaroslav and Valík, Dalibor and Múdry, Peter and Kepák, Tomáš and Pavelka, Zdeněk and Bajčiová, Viera and Zitterbart, Karel and Kadlecoá, Věra and Mazánek, Pavel},
   article_location = {Switzerland},
   article_number = {7},
   keywords = {childhood cancer; metronomic therapy; biotherapy},
   language = {eng},
   issn = {0378-584X},
   journal = {Onkologie},
   title = {Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study.},
   volume = {29},
   year = {2006}
}

TY  - JOUR
ID  - 839465
AU  - Štěrba, Jaroslav - Valík, Dalibor - Múdry, Peter - Kepák, Tomáš - Pavelka, Zdeněk - Bajčiová, Viera - Zitterbart, Karel - Kadlecoá, Věra - Mazánek, Pavel
PY  - 2006
TI  - Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study.
JF  - Onkologie
VL  - 29
IS  - 7
SP  - 308-313
EP  - 308-313
PB  - Karger
SN  - 0378584X
KW  - childhood cancer
KW  - metronomic therapy
KW  - biotherapy
N2  - Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study.To outline an outpatient-based treatment for children with relapsed solid tumors, who already have been extensively pretreated, we defined a 4-drug protocol named COMBAT (combined oral maintenance biodifferentiating and antiangiogenic therapy). Using this protocol, we performed a pilot study to determine its feasibility in children with relapsed and/or high-risk pediatric solid tumors. Patients and Methods: 22 children received the COMBAT protocol. Treatment consisted of daily celecoxib administration along with daily 13-cisretinoic acid (2 weeks on / 2 weeks off) and cycles of metronomic temozolomide (90 mg/m2 for 42 days) and low-dose etoposide (21 days). The treatment was scheduled for a period of 1 year. Results: 9 of the 14 patients assessable for response demonstrated evidence of treatment benefit manifested as prolonged disease stabilization or response. The protocol medication was well tolerated with very good compliance. Only minimal side effects where observed which responded to dose modification or local therapy. Conclusions: The COMBAT regimen is well tolerated by patients with intensive prior therapy including myeloablative regimens. Favorable responses observed in this cohort of patients support the further exploration of this and/or similar strategies in the treatment of pediatric solid tumors.
ER  -

ŠTĚRBA, Jaroslav; Dalibor VALÍK; Peter MÚDRY; Tomáš KEPÁK; Zdeněk PAVELKA; Viera BAJČIOVÁ; Karel ZITTERBART; Věra KADLECOÁ a Pavel MAZÁNEK. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. \textit{Onkologie}. Switzerland: Karger, 2006, roč.~29, č.~7, s.~308-313, 5 s. ISSN~0378-584X.

Přehled o publikaci